Pulmonary Embolism Diagnostic Market: Global Industry Analysis, Trends, Size, Growth and Forecasts to 2017-2021 – MarketReportsOnline
MarketReportsOnline.com adds “Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)” report to its research store.
Pune, India – April 27, 2017 /MarketersMedia/ —
The report titled “Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)”, provides an in-depth analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of patients), by segments, etc. The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis of diagnostics penetration and the regions such as the US with an addressable market opportunity for the diagnostics penetration.
Company Coverage of Global Pulmonary Embolism Diagnostic Market: cyclopharm, jubilant lifesciences limited, philips & siemens
Complete report on Pulmonary Embolism Diagnostic industry spread across 75 pages with providing 4 company Profiles, 3 tables and 31 figures is now available at http://www.marketreportsonline.com/585820.html.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the pulmonary embolism diagnostics market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The competition in the pulmonary embolism diagnostic market, especially V/Q scan is dominated by one big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by Lantheus Holdings, Inc. (Xe-133).
Further, key players of the global pulmonary thromboembolism diagnostic market Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective business strategies.
Country Coverage of Pulmonary Embolism Diagnostic Market: Developed Regions (Canada, Europe, Australia and Parts of Asia) & US
Venous Thromboembolism (VTE) is a type of blood clot that starts in the vein. Most commonly VTE starts in the legs of the patient, however, it could occur in any other part of the body also. There are two types of VTE: Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE).
The pulmonary embolism generally occurs due to DVTs or pelvic vein thrombosis.
Purchase a copy of this “Global Pulmonary Embolism Diagnostics Market” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=585820.
Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a tendency to block a blood vessel in the lungs and hence damage them.
Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery, genetic blood clotting disorder or fracture of the hip or leg, etc. The onset of pulmonary embolism is depicted by shortness of breath, sudden chest pain and coughing blood. These symptoms are then followed by other symptoms such as flank pain, wheezing, cardiac murmur, etc.
There are different types of tests done to detect pulmonary embolism, however, Computed Tomography Pulmonary Angiogram (CTPA) is the gold standard for detecting pulmonary embolism. Another alternative test done to detect pulmonary embolism is Ventilation-Perfusion (V/Q) Scanning.
The global pulmonary embolism diagnostics market is anticipated to increase at a significant CAGR during the years 2017-2021. The pulmonary embolism diagnostic market is expected to increase due to growth in number of cancer patients, aging population, increase in per-capita healthcare expenditure, etc. Yet the market faces some challenges such as, prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of Novel Oral anticoagulants.
Since prevention is better than cure, a healthy lifestyle is most commonly prescribed to prevent pulmonary embolism. However, pulmonary embolism is managed majorly through intake of anticoagulants, thrombolytics, vena cava filter and compression stockings.
Few Points from List of Tables & Figures:
List of Tables
Table 1: The US Pulmonary Embolism Diagnostic Technegas Addressable Market; 2015
Table 2: Mo99 Isotope Cost Savings for the End-User
Table 3: Global Players in Pulmonary Embolism Market: A Financial; 2016
List of Figures
Figure 1: Types of Venous Thromboembolism (VTE)
Figure 2: Risk Factors of Pulmonary Embolism
Figure 3: Prominent Symptoms of Pulmonary Embolism
Figure 4: Other Symptoms of Pulmonary Embolism
Figure 5: Physical Signs of Pulmonary Embolism
Figure 6: Laboratory Tests for Pulmonary Embolism
Figure 7: Types of Gaseous Radionuclides in V/Q Scan
Figure 8: Management of Pulmonary Embolism
Figure 9: Prevention of Pulmonary Embolism
Figure 10: Developed Region Pulmonary Embolism Diagnostic Market by Value; 2015-2021 (US$ Million)
Explore more Pharmaceuticals market research as well as other newly published reports by Daedal Research at http://www.marketreportsonline.com/publisher/daedal-research-market-research.html.
Contact Info:
Name: Ritesh Tiwari
Email: sales@marketreportsonline.com
Organization: MarketReportsOnline
Phone: + 1 888 391 5441
For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=585820
Source: MarketersMedia
Release ID: 191361
Copyright © 1999-2013 SproutNews.com
